Geron (GERN) to Release Quarterly Earnings on Wednesday

Geron (NASDAQ:GERN) will likely be announcing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 25, 2026 at 8:00 AM ET.

Geron Stock Up 9.1%

Shares of NASDAQ:GERN opened at $1.80 on Wednesday. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -15.00 and a beta of 0.62. The company has a 50 day moving average of $1.41 and a two-hundred day moving average of $1.33. Geron has a 52-week low of $1.04 and a 52-week high of $2.70. The company has a quick ratio of 4.87, a current ratio of 5.96 and a debt-to-equity ratio of 0.48.

Institutional Trading of Geron

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Caitong International Asset Management Co. Ltd grew its holdings in Geron by 3,307.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 24,410 shares during the period. Amundi acquired a new stake in Geron in the 4th quarter valued at about $38,000. Franklin Resources Inc. bought a new position in shares of Geron during the 3rd quarter valued at about $45,000. Cibc World Markets Corp bought a new position in shares of Geron during the 4th quarter valued at about $48,000. Finally, Atom Investors LP grew its stake in shares of Geron by 137.0% in the 4th quarter. Atom Investors LP now owns 37,341 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 21,588 shares during the last quarter. 73.71% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

GERN has been the topic of several research analyst reports. Needham & Company LLC reduced their price objective on Geron from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday, November 5th. UBS Group restated a “neutral” rating on shares of Geron in a research report on Tuesday, December 9th. TD Cowen reaffirmed a “buy” rating on shares of Geron in a research report on Thursday, January 29th. HC Wainwright reiterated a “neutral” rating on shares of Geron in a research note on Tuesday, December 9th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Geron in a report on Wednesday, January 28th. Four investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $2.75.

Geron Company Profile

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.